For the first time in an annual report on tobacco by the U.S. Surgeon General’s office, smoking was linked to diabetes, rheumatoid arthritis, macular degeneration, ectopic pregnancies and impaired immune function. And in addition to lung cancer, 13 other cancers have now been linked to the habit and secondhand smoke …
Read More »Yearly Archives: 2014
SGLT-2 Inhibitor and Metformin Combination Drug Approved in Europe
European regulators have approved Xigduo for type 2 diabetes in the first green light for a fixed dose combination of an SGLT2 inhibitor and metformin. The drug combines in a twice daily tablet dapagliflozin an SGLT2 inhibitor that reduces the reabsorption of excess glucose, and metformin. FDA News Release
Read More »24M People Will Use Diabetes Apps in 2018:
Today only 1.6 million of people with diabetes who own a smartphone use a mobile application to manage their diabetes. However, the Research Guidance firm predicts that by 2018 that number will rise to 24 million users, or 7.8% of smartphone owners with diabetes. Changes in the conception of mobile apps, from …
Read More »Updated Recommendations on Aspirin Therapy in Diabetic Patients
An overview on aspirin use in the prevention of cardiovascular events…. Aspirin is a pharmaceutical drug that has been commercially available since 1899. Although originally used as a pain reliever and fever reducer, significant studies show aspirin can play a role in reducing the risk of cardiovascular disease. Patients with …
Read More »Ipragliflozin and HbA1C Levels
How does SGLT-2 inhibitor, ipragliflozon compare to metformin alone?…. Ipragliflozin is an oral medication in development by Astellas Pharma for the treatment of type 2 diabetes. A novel selective sodium glucose co-transporter-2 (SGLT-2) inhibitor, ipragliflozin works similarly to the first in class marketed SGLT-2 inhibitor drug, canagliflozin, by increasing urinary …
Read More »Treatment with Ipragliflozin + Metformin
Combination well-tolerated in patients with type 2 diabetes…. Ipragliflozin is an oral medication in development by Astellas Pharma for the treatment of type 2 diabetes. A novel selective sodium glucose co-transporter-2 (SGLT-2) inhibitor, ipragliflozin works similarly to the first in class marketed SGLT-2 inhibitor drug canagliflozin by increasing urinary excretion …
Read More »Blood Type Diet: Fact or Fiction?
Popular nutritional diet method examined by researchers….
Read More »Traditional Chinese Medicine May Be Beneficial in Diabetes Prevention
Can taking a mixture of herbs three times daily help moderate glucose levels?…
Read More »Muscle Strengthening Activities Could Help Protect against Diabetes
Performing certain activities as little as 30 minutes per week could help reduce risks….
Read More »How High Fiber Diets Protect against Diabetes and Obesity
Fermentable fibers such as cabbage, beans, and some fruits and vegetables increase satiety….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.